New device enables improved retinal imaging in periphery

Article

The P200C, a retinal imaging device designed for advanced ocular disease, has been launched by Optos plc.

The P200C, a retinal imaging device designed for advanced ocular disease, has been launched by Optos plc. This device is complementary to the firm's Panoramic200 Scanning Laser Ophthalmoscope (P200), which is used for the early detection of retinal conditions such as glaucoma, diabetic retinopathy and age-related macular degeneration, and for non-eye diseases including diabetes and hypertension.

The P200C is intended to be used in the advanced clinical optometry and ophthalmology markets. Its design improves image accuracy, allowing the capture of images in the mid to very far periphery of the retina by potentially reaching the ora serrata and increasing productivity with its ergonomic patient interface.

Optos plans to market the P200C primarily on a pay-per-patient basis to an estimated 10,000 addressable practice locations in its existing markets of the UK, Germany, the US and Canada.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.